Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1973 1
1977 2
1979 2
1980 1
1981 4
1982 5
1983 1
1985 2
1986 2
1987 1
1988 1
1989 3
1990 9
1991 15
1992 11
1993 16
1994 15
1995 12
1996 6
1997 11
1998 5
1999 8
2000 7
2001 12
2002 12
2003 6
2004 11
2005 13
2006 12
2007 15
2008 24
2009 24
2010 30
2011 23
2012 22
2013 28
2014 30
2015 26
2016 26
2017 39
2018 31
2019 16
2020 27
2021 21
2022 28
2023 16
2024 31
2025 13
2026 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

613 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.
Mackenzie IS, Ford I, Nuki G, Hallas J, Hawkey CJ, Webster J, Ralston SH, Walters M, Robertson M, De Caterina R, Findlay E, Perez-Ruiz F, McMurray JJV, MacDonald TM; FAST Study Group. Mackenzie IS, et al. Lancet. 2020 Nov 28;396(10264):1745-1757. doi: 10.1016/S0140-6736(20)32234-0. Epub 2020 Nov 9. Lancet. 2020. PMID: 33181081 Free article. Clinical Trial.
BACKGROUND: Febuxostat and allopurinol are urate-lowering therapies used to treat patients with gout. Following concerns about the cardiovascular safety of febuxostat, the European Medicines Agency recommended a post-licensing study assessing the cardiovascular safety of f …
BACKGROUND: Febuxostat and allopurinol are urate-lowering therapies used to treat patients with gout. Following concerns about the ca …
Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N. Becker MA, et al. N Engl J Med. 2005 Dec 8;353(23):2450-61. doi: 10.1056/NEJMoa050373. N Engl J Med. 2005. PMID: 16339094 Free article. Clinical Trial.
Although the incidence of gout flares diminished with continued treatment, the overall incidence during weeks 9 through 52 was similar in all groups: 64 percent of patients receiving 80 mg of febuxostat, 70 percent of those receiving 120 mg of febuxostat, and 64 percent of those …
Although the incidence of gout flares diminished with continued treatment, the overall incidence during weeks 9 through 52 was similar in al …
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.
White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, Hunt B, Castillo M, Gunawardhana L; CARES Investigators. White WB, et al. N Engl J Med. 2018 Mar 29;378(13):1200-1210. doi: 10.1056/NEJMoa1710895. Epub 2018 Mar 12. N Engl J Med. 2018. PMID: 29527974 Free article. Clinical Trial.
We compared cardiovascular outcomes associated with febuxostat, a nonpurine xanthine oxidase inhibitor, with those associated with allopurinol, a purine base analogue xanthine oxidase inhibitor, in patients with gout and cardiovascular disease. ...CONCLUSIONS: In patients …
We compared cardiovascular outcomes associated with febuxostat, a nonpurine xanthine oxidase inhibitor, with those associated with allopu …
Effects of Allopurinol on the Progression of Chronic Kidney Disease.
Badve SV, Pascoe EM, Tiku A, Boudville N, Brown FG, Cass A, Clarke P, Dalbeth N, Day RO, de Zoysa JR, Douglas B, Faull R, Harris DC, Hawley CM, Jones GRD, Kanellis J, Palmer SC, Perkovic V, Rangan GK, Reidlinger D, Robison L, Walker RJ, Walters G, Johnson DW; CKD-FIX Study Investigators. Badve SV, et al. N Engl J Med. 2020 Jun 25;382(26):2504-2513. doi: 10.1056/NEJMoa1915833. N Engl J Med. 2020. PMID: 32579811 Clinical Trial.
Whether urate-lowering treatment with allopurinol can attenuate the decline of the estimated glomerular filtration rate (eGFR) in patients with chronic kidney disease who are at risk for progression is not known. ...Serious adverse events were reported in 84 of 182 patient …
Whether urate-lowering treatment with allopurinol can attenuate the decline of the estimated glomerular filtration rate (eGFR) in pat …
Efficacy and Safety of Allopurinol and Febuxostat in Patients With Gout and CKD: Subgroup Analysis of the STOP Gout Trial.
Helget LN, Davis-Karim A, O'Dell JR, Mikuls TR, Newcomb JA, Androsenko M, Brophy MT, England BR, Ferguson R, Pillinger MH, Neogi T, Wu H, Palevsky PM. Helget LN, et al. Am J Kidney Dis. 2024 Nov;84(5):538-545. doi: 10.1053/j.ajkd.2024.04.017. Epub 2024 Jun 19. Am J Kidney Dis. 2024. PMID: 38906504 Clinical Trial.
CONCLUSIONS: Allopurinol and febuxostat are similarly efficacious and well-tolerated in the treatment of gout in people with CKD when used in a treat-to-target regimen with lower incidence of gout flares in participants randomized to allopurinol. ...A significant pr …
CONCLUSIONS: Allopurinol and febuxostat are similarly efficacious and well-tolerated in the treatment of gout in people with CKD when …
Allopurinol use and the risk of dementia: A meta-analysis of case-control studies.
Lai SW, Hwang BF, Kuo YH, Liu CS, Liao KF. Lai SW, et al. Medicine (Baltimore). 2022 Jul 1;101(26):e29827. doi: 10.1097/MD.0000000000029827. Medicine (Baltimore). 2022. PMID: 35777042 Free PMC article.
BACKGROUND: This study aimed to compare the risk of dementia between exposed to allopurinol and not exposed to allopurinol in persons who had gout and/or hyperuricemia. ...The mean age of study persons was from 72.3 to 78.7 years. Overall, the odds of the allopur …
BACKGROUND: This study aimed to compare the risk of dementia between exposed to allopurinol and not exposed to allopurinol in …
Effects of Allopurinol Dose Escalation on Bone Erosion and Urate Volume in Gout: A Dual-Energy Computed Tomography Imaging Study Within a Randomized, Controlled Trial.
Dalbeth N, Billington K, Doyle A, Frampton C, Tan P, Aati O, Allan J, Drake J, Horne A, Stamp LK. Dalbeth N, et al. Arthritis Rheumatol. 2019 Oct;71(10):1739-1746. doi: 10.1002/art.40929. Epub 2019 Aug 12. Arthritis Rheumatol. 2019. PMID: 31081595 Clinical Trial.
OBJECTIVE: To examine whether allopurinol dose escalation to achieve serum urate (SU) target can influence bone erosion or monosodium urate (MSU) crystal deposition, as measured by dual-energy computed tomography (DECT) in patients with gout. METHODS: We conducted an imagi …
OBJECTIVE: To examine whether allopurinol dose escalation to achieve serum urate (SU) target can influence bone erosion or monosodium …
Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes.
Doria A, Galecki AT, Spino C, Pop-Busui R, Cherney DZ, Lingvay I, Parsa A, Rossing P, Sigal RJ, Afkarian M, Aronson R, Caramori ML, Crandall JP, de Boer IH, Elliott TG, Goldfine AB, Haw JS, Hirsch IB, Karger AB, Maahs DM, McGill JB, Molitch ME, Perkins BA, Polsky S, Pragnell M, Robiner WN, Rosas SE, Senior P, Tuttle KR, Umpierrez GE, Wallia A, Weinstock RS, Wu C, Mauer M; PERL Study Group. Doria A, et al. N Engl J Med. 2020 Jun 25;382(26):2493-2503. doi: 10.1056/NEJMoa1916624. N Engl J Med. 2020. PMID: 32579810 Free PMC article. Clinical Trial.
Lowering of the serum urate level with allopurinol may slow the decrease in the glomerular filtration rate (GFR) in persons with type 1 diabetes and early-to-moderate diabetic kidney disease. ...The mean baseline iohexol-based GFR was 68.7 ml per minute per 1.73 m(2) in th …
Lowering of the serum urate level with allopurinol may slow the decrease in the glomerular filtration rate (GFR) in persons with type …
Allopurinol to reduce cardiovascular morbidity and mortality: A systematic review and meta-analysis.
van der Pol KH, Wever KE, Verbakel M, Visseren FLJ, Cornel JH, Rongen GA. van der Pol KH, et al. PLoS One. 2021 Dec 2;16(12):e0260844. doi: 10.1371/journal.pone.0260844. eCollection 2021. PLoS One. 2021. PMID: 34855873 Free PMC article.
AIMS: To compare the effectiveness of allopurinol with no treatment or placebo for the prevention of cardiovascular events in hyperuricemic patients. ...Cardiovascular benefit was only observed when allopurinol therapy was prolonged for more than 6 months and when a …
AIMS: To compare the effectiveness of allopurinol with no treatment or placebo for the prevention of cardiovascular events in hyperur …
Comparative efficacy and safety of febuxostat and allopurinol in chronic kidney disease stage 3-5 patients with asymptomatic hyperuricemia: a network meta-analysis.
Chen J, Zhang Y, Wang Y, Chen L. Chen J, et al. Ren Fail. 2025 Dec;47(1):2470478. doi: 10.1080/0886022X.2025.2470478. Epub 2025 Feb 27. Ren Fail. 2025. PMID: 40012480 Free PMC article.
OBJECTIVE: This study evaluates and compares the effectiveness and safety of febuxostat and allopurinol in chronic kidney disease (CKD) stages 3-5 patients with asymptomatic hyperuricemia using a network meta-analysis. ...Safety outcomes, including major cardiovascular eve …
OBJECTIVE: This study evaluates and compares the effectiveness and safety of febuxostat and allopurinol in chronic kidney disease (CK …
613 results